FY2026 EPS Estimates for C4 Therapeutics, Inc. (NASDAQ:CCCC) Lifted by Jefferies Financial Group

C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Rating) – Equities research analysts at Jefferies Financial Group boosted their FY2026 earnings per share estimates for shares of C4 Therapeutics in a report issued on Monday, April 18th. Jefferies Financial Group analyst K. Shi now expects that the company will post earnings of ($4.83) per share for the year, up from their prior estimate of ($4.98).

C4 Therapeutics (NASDAQ:CCCC – Get Rating) last announced its quarterly earnings results on Thursday, February 24th. The company reported ($0.31) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.28. C4 Therapeutics had a negative net margin of 183.23% and a negative return on equity of 22.85%. The company had revenue of $20.08 million for the quarter, compared to analyst estimates of $7.16 million.

A number of other research analysts have also issued reports on CCCC. Zacks Investment Research upgraded shares of C4 Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 1st. UBS Group lowered their target price on shares of C4 Therapeutics from $64.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday. JPMorgan Chase & Co. assumed coverage on shares of C4 Therapeutics in a research note on Thursday, March 10th. They issued an “overweight” rating and a $43.00 target price on the stock. Wells Fargo & Company assumed coverage on shares of C4 Therapeutics in a research report on Thursday, February 10th. They issued an “equal weight” rating and a $25.00 price target on the stock. Finally, Stifel Nicolaus decreased their price target on shares of C4 Therapeutics from $28.00 to $15.00 in a research report on Monday, April 11th. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $31.60.

NASDAQ:CCCC opened at $9.43 on Wednesday. C4 Therapeutics has a 1 year low of $7.51 and a 1 year high of $51.21. The firm has a fifty day moving average price of $20.88. The company has a quick ratio of 6.36, a current ratio of 6.36 and a debt-to-equity ratio of 0.03. The firm has a market cap of $459.61 million, a price-to-earnings ratio of -5.18 and a beta of 1.45.

In other C4 Therapeutics news, CEO Andrew Hirsch acquired 10,000 shares of C4 Therapeutics stock in a transaction dated Tuesday, April 12th. The stock was bought at an average cost of $8.40 per share, with a total value of $84,000.00. Following the acquisition, the chief executive officer now owns 10,000 shares of the company’s stock, valued at $84,000. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 21.04% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. Migdal Insurance & Financial Holdings Ltd. bought a new position in C4 Therapeutics during the 3rd quarter valued at about $53,000. Nisa Investment Advisors LLC lifted its holdings in C4 Therapeutics by 134.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,620 shares of the company’s stock valued at $40,000 after purchasing an additional 930 shares during the last quarter. Point72 Hong Kong Ltd lifted its holdings in C4 Therapeutics by 49.7% during the 4th quarter. Point72 Hong Kong Ltd now owns 2,011 shares of the company’s stock valued at $65,000 after purchasing an additional 668 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in C4 Therapeutics during the 4th quarter valued at about $110,000. Finally, Russell Investments Group Ltd. lifted its holdings in C4 Therapeutics by 799.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 5,056 shares of the company’s stock valued at $225,000 after purchasing an additional 4,494 shares during the last quarter. 70.14% of the stock is owned by hedge funds and other institutional investors.

About C4 Therapeutics (Get Rating)

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.

Recommended Stories